v3.25.1
Condensed Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2023   37,518,583      
Balance at beginning of period at Dec. 31, 2023 $ 15,103 $ 37 $ 118,193 $ 120 $ (103,247)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   246,692      
Issuance of common stock upon exercise of stock options 255   255    
Issuance of common stock for settlement of Restricted Stock Units (RSUs) (in shares)   526,150      
Issuance of common stock for settlement of Restricted Stock Units (RSUs) 0 $ 1 (1)    
Stock-based compensation expense 3,657   3,657    
Unrealized losses on available-for-sale securities, net of tax (66)     (66)  
Net loss (9,403)       (9,403)
Balance at end of period (in shares) at Mar. 31, 2024   38,291,425      
Balance at end of period at Mar. 31, 2024 $ 9,546 $ 38 122,104 54 (112,650)
Balance at beginning of period (in shares) at Dec. 31, 2024 40,724,936 40,724,936      
Balance at beginning of period at Dec. 31, 2024 $ (1,188) $ 40 135,522 135 (136,885)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares) 145,959 145,959      
Issuance of common stock upon exercise of stock options $ 148   148    
Issuance of common stock for settlement of Restricted Stock Units (RSUs) (in shares)   532,399      
Issuance of common stock for settlement of Restricted Stock Units (RSUs) 0 $ 1 (1)    
Stock-based compensation expense 4,346   4,346    
Unrealized losses on available-for-sale securities, net of tax (6)     (6)  
Net loss $ (8,121)       (8,121)
Balance at end of period (in shares) at Mar. 31, 2025 41,403,294 41,403,294      
Balance at end of period at Mar. 31, 2025 $ (4,821) $ 41 $ 140,015 $ 129 $ (145,006)